SV2008002477A - COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY REF. BHC051038-SV - Google Patents

COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY REF. BHC051038-SV

Info

Publication number
SV2008002477A
SV2008002477A SV2006002477A SV2006002477A SV2008002477A SV 2008002477 A SV2008002477 A SV 2008002477A SV 2006002477 A SV2006002477 A SV 2006002477A SV 2006002477 A SV2006002477 A SV 2006002477A SV 2008002477 A SV2008002477 A SV 2008002477A
Authority
SV
El Salvador
Prior art keywords
bhc051038
ref
combination
benign hyperplasia
hyperplasia therapy
Prior art date
Application number
SV2006002477A
Other languages
Spanish (es)
Inventor
Helmut Haning
Peter Serno
Erwin Bischoff
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of SV2008002477A publication Critical patent/SV2008002477A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Abstract

ESTA INVENCIÓN SE REFIERE A UN PROCEDIMIENTO NOVEDOSO PARA EL TRATAMIENTO DE SÍNTOMAS EN HIPERPLASIA BENIGNA DE PRÓSTATA. A ESTE RESPECTO SE USAN DE FORMA SIMULTÁNEA: (1) UN ANTAGONISTA DEL ADRENORECEPTOR ALFA-1 EN FORMULACIÓN DE LIBERACIÓN CONTROLADA O UN INHIBIDOR DE 5-ALFA-REDUCTASA Y (2) UN INHIBIDOR DE PDE DE GMPC EN FORMULACION DE LIBERACION CONTROLADA O UN INHIBIDOR DE PDE 5 DE GMPC CON MAYOR TIEMPO DE SEMIVIDATHIS INVENTION CONCERNS A NEW PROCEDURE FOR THE TREATMENT OF SYMPTOMS IN BENIGN HYPERPLASIA OF PROSTATE. IN THIS REGARD, THEY ARE USED SIMULTANEOUSLY: (1) AN ALGON-1 ADRENORECEPTOR ANTAGONIST IN CONTROLLED RELEASE FORMULATION OR A 5-ALFA-REDUCTASE INHIBITOR AND (2) A GMPC PDE INHIBITOR IN CONTROLLED RELEASE FORMULATION OR A GMPC PDE 5 INHIBITOR WITH GREATER TIME OF SEMIVIDE

SV2006002477A 2005-04-13 2006-04-07 COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY REF. BHC051038-SV SV2008002477A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102005016981A DE102005016981A1 (en) 2005-04-13 2005-04-13 Combination therapy for benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
SV2008002477A true SV2008002477A (en) 2008-02-08

Family

ID=36608700

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2006002477A SV2008002477A (en) 2005-04-13 2006-04-07 COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY REF. BHC051038-SV

Country Status (22)

Country Link
EP (1) EP1888075A1 (en)
JP (1) JP2008535877A (en)
KR (1) KR20080007252A (en)
CN (1) CN101193638A (en)
AR (1) AR053575A1 (en)
AU (1) AU2006233567A1 (en)
BR (1) BRPI0610634A2 (en)
CA (1) CA2605224A1 (en)
CR (1) CR9427A (en)
DE (1) DE102005016981A1 (en)
DO (1) DOP2006000074A (en)
GT (1) GT200600145A (en)
IL (1) IL186604A0 (en)
MA (1) MA29683B1 (en)
MX (1) MX2007012567A (en)
PE (1) PE20061338A1 (en)
RU (1) RU2007141518A (en)
SV (1) SV2008002477A (en)
TN (1) TNSN07385A1 (en)
TW (1) TW200716122A (en)
UY (1) UY29473A1 (en)
WO (1) WO2006108519A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
WO2007047282A1 (en) * 2005-10-12 2007-04-26 Lilly Icos Llc Treatment of benign prostatic hypertrophy and lower urinary tract symptoms
EP1968705A1 (en) * 2005-12-21 2008-09-17 Pfizer Products Incorporated Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
DE102007028869A1 (en) 2007-06-22 2008-12-24 Ratiopharm Gmbh A process for the preparation of a medicament containing tadalafil
MX2010006520A (en) 2007-12-13 2010-11-30 Vanda Pharmaceuticals Inc Method and composition for treating an alpha adrenoceptor-mediate d condition.
PL2222300T3 (en) 2007-12-13 2015-02-27 Vanda Pharmaceuticals Inc Method and composition for treating a serotonin receptor-mediated condition
US8737368B2 (en) 2010-04-26 2014-05-27 Intel Corporation Method, apparatus and system for switching traffic streams among multiple frequency bands
WO2013123965A1 (en) * 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
CN102727456B (en) * 2012-07-03 2016-06-22 北京科信必成医药科技发展有限公司 Drug port cavity disintegrating tablet and preparation method thereof
EA039091B1 (en) * 2013-06-28 2021-12-02 Ханми Фарм. Ко., Лтд. Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin
AU2014293141A1 (en) 2013-07-23 2016-02-18 Serenity Pharmaceuticals Llc Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist
KR101663238B1 (en) * 2013-11-15 2016-10-14 한미약품 주식회사 Complex solid formulation comprising tadalafil and amlodipine
MY181172A (en) * 2014-06-30 2020-12-21 Hanmi Pharm Ind Co Ltd Composite preparation comprising active ingredient-containing film coating layer
WO2016003181A1 (en) * 2014-06-30 2016-01-07 한미약품 주식회사 Composite preparation comprising active ingredient-containing film coating layer
ES2781110T3 (en) * 2014-06-30 2020-08-28 Hanmi Pharm Ind Co Ltd Composite material preparation comprising a film coating layer, containing a 5-alpha-reductase inhibitor, and method for the production of the composite material preparation
CA2967390A1 (en) * 2014-11-20 2016-05-26 Allergan, Inc. Methods and compositions comprising desmopressin in combination with an alpha-adrenergic receptor antagonist
US20190125685A1 (en) * 2016-03-31 2019-05-02 Hanmi Pharm. Co., Ltd. Composite capsule preparation containing tadalafil and tamsulosin and having improved stability and elution rate
KR101835506B1 (en) * 2016-10-25 2018-03-07 주식회사 에스텍파마 Rapid-acting mixture of tablet containing dutasteride and tadalafil
CN108066347B (en) * 2016-11-16 2021-02-02 深圳万和制药有限公司 Orally disintegrating tablet pharmaceutical composition comprising tamsulosin and dutasteride
KR101879133B1 (en) * 2017-07-11 2018-07-17 (주)동구바이오제약 Agents for preventing or treating urinary disease and preparing the same
TR201715231A2 (en) * 2017-10-09 2019-04-22 Montero Gida Sanayi Ve Ticaret Anonim Sirketi The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050042177A1 (en) * 2003-07-23 2005-02-24 Elan Pharma International Ltd. Novel compositions of sildenafil free base

Also Published As

Publication number Publication date
AU2006233567A1 (en) 2006-10-19
DE102005016981A1 (en) 2006-10-19
IL186604A0 (en) 2008-01-20
CR9427A (en) 2007-12-17
KR20080007252A (en) 2008-01-17
RU2007141518A (en) 2009-05-20
EP1888075A1 (en) 2008-02-20
MA29683B1 (en) 2008-08-01
WO2006108519A1 (en) 2006-10-19
MX2007012567A (en) 2007-12-10
PE20061338A1 (en) 2007-01-28
TW200716122A (en) 2007-05-01
TNSN07385A1 (en) 2009-03-17
CN101193638A (en) 2008-06-04
UY29473A1 (en) 2006-11-30
DOP2006000074A (en) 2006-10-15
GT200600145A (en) 2007-04-10
JP2008535877A (en) 2008-09-04
AR053575A1 (en) 2007-05-09
BRPI0610634A2 (en) 2010-07-13
CA2605224A1 (en) 2006-10-19

Similar Documents

Publication Publication Date Title
SV2008002477A (en) COMBINATION FOR PROSTATE BENIGN HYPERPLASIA THERAPY REF. BHC051038-SV
AR045179A1 (en) USE OF A COMBINATION OF AN INHIBITOR OF THE KINASA OF THE RECEIVER OF THE EPIDERMAL GROWTH FACTOR AND OF CYTOTOXIC AGENTS FOR THE TREATMENT AND INHIBITION OF CANCER
SV2007002146A (en) DIFENYLIMIDAZOPIRIMIDINE AND IMIDAZOL AMINAS AS BETA-SECRETASA INHIBITORS REF. AM101727
NI200500148A (en) ANTINEOPLASIC COMBINATIONS THAT INCLUDE A RAPAMYCIN DERIVATIVE AND A ROTAMASS INHIBITOR.
CL2007003523A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE ACTIVITY OF PI3 QUINASA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE IN THE CANCER PROFILACTIC OR THERAPEUTIC TREATMENT
ECSP099724A (en) USE OF PI3K-ALFA PYRIDOPIRIMIDINONE INHIBITORS IN CANCER TREATMENT
ECSP077426A (en) USE OF A MTOR INHIBITOR IN THE UTERINE LEIOMIOMA TREATMENT
CL2007002261A1 (en) COMPOUNDS DERIVED FROM IMIDAZO [1,2-B] PIRIDAZINA, QUINASA INHIBITORS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OR PREVENTION OF CANCER.
CL2007002384A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the treatment of psoriasis.
AR048819A1 (en) SYNERGIC METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER
WO2008097525A3 (en) Local complement inhibition for treatment of complement-mediated disorders
CL2010001483A1 (en) Compounds derived from 5-phenyl-1h-pyridin-2-one and 6-phenyl-2h-pyridazin-3-one, tyrosine kinase inhibitors (btk); Pharmaceutical composition comprising said compounds and their use for the treatment of an inflammatory and / or autoimmune pathological state.
NZ595572A (en) Inhibitors of pi3 kinase and / or mtor
MX2009013729A (en) Imidazopyrazines as protein kinase inhibitors.
ECSP088752A (en) FORMULATIONS FOR PARENTERAL ADMINISTRATION OF COMPOUNDS AND THEIR USES
ECSP099723A (en) USE OF PI3K-ALFA QUINAXOLINE INHIBITING COMPOUNDS FOR CANCER TREATMENT
NO20080626L (en) Inhibitors of fibroblast activating protein alpha
AR047568A1 (en) ENDOPROTESIS COVERED WITH THERAPEUTICALLY ACTIVE PHARMACO.
CL2012002887A1 (en) Pharmaceutical combination comprising compounds derived from substituted 2,3-dihydroimidazo [1,2-c] quinazoline, compounds derived from n- (2-arylamino) arylsulfonamide and optionally other additional pharmaceutical agents; pharmaceutical kit; treatment method; and its use for the treatment or prophylaxis of cancer.
CL2007003557A1 (en) COMPOUNDS DERIVED FROM NITROGEN HETEROCICLES, INHIBITORS OF THE ACTIVITY ON B-RAF; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CANCER.
CL2008000021A1 (en) Compounds derived from 2,4-dianilinopyrimidines, protein kinase inhibitors; preparation procedure; pharmaceutical composition; and use for the treatment or prevention of inflammatory diseases, diabetes, and cancer.
CL2007002380A1 (en) Use of compounds derived from 2,5-dihydroxybenzene for the therapeutic and / or prophylactic treatment of actinic keratosis.
AR039987A1 (en) USE OF SENAL TRANSDUCTION INHIBITORS INDIRECTED BY EGFR FOR THE TREATMENT OF HYPERPLASIA OF THE BENIGNA PROSTATE (BPH) / PROSTATE HYPERTROPHY
CL2007003251A1 (en) Compounds derived from substituted 1H-pyrazoles, inhibitors of kinase-catalyzed reactions; its preparation procedure; pharmaceutical composition; intermediate compounds; use of the main compounds, useful in the treatment of cancer.
CO2022000270A2 (en) enzyme inhibitors

Legal Events

Date Code Title Description
FD Lapse